Effect of Diacerein in the Metabolic Control of Patients With DM Type 2 and Secondary Failure to Metformin
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Considering that, Diacerein is on the market for almost 20 years, being used continuously in
elderly patients with osteoarthritis without present significant side effects, and
considering the anti-hyperglycemic effect and the improvement in the insulin resistance
observed in animal models of type 2 diabetes and in a previously study from Mexico. The aim
of our study is to investigate the effect of Diacerein, a medication with anti-osteoarthritic
properties and moderately analgesic activity, anti-inflammatory and antipyretic, which
demonstrates inhibit properties for the synthesis of pro-inflammatory cytokines such as
interleukin 1 (IL-1). Administered for 12 weeks and the effect in the glycemic and metabolic
control in patients with diabetes mellitus 2 and secondary failure to metformin treatment.
Phase:
Phase 2
Details
Lead Sponsor:
University of Campinas, Brazil
Collaborators:
ANS Pharma Conselho Nacional de Desenvolvimento Científico e Tecnológico